Marc Better

Dr. Better is a biotechnology professional with more than 25 years’ experience in cell therapy and biologics CMC. He is currently a principal consultant at Pharmefex Biopharma Consulting. Prior to Pharmefex, Dr. Better was Senior Vice President, Product Sciences at Kite, a Gilead Company, where he led process and analytical development, process characterization and process validation activities leading to the successful US licensure of Yescarta®, a first in class anti-CD19 CAR T cell therapy. Prior to Kite, Dr. Better held leadership roles in biologics process development and manufacturing at Boehringer Ingelheim, Amgen/Abgenix, and Xoma.